Compass Therapeutics financials
$1.10−0.90%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $850.0K | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $850.0K | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | 100.0% | — | — | — |
| Operating income | -$27.0M | -$20.3M | -$18.0M | -$15.8M | -$21.1M | -$18.0M | -$16.6M | -$12.2M | -$15.0M | -$12.8M | -$15.4M | -$11.9M |
| Net income | -$25.2M | -$18.3M | -$15.7M | -$14.3M | -$19.9M | -$16.6M | -$15.0M | -$10.5M | -$13.1M | -$10.8M | -$13.4M | -$10.0M |
| Net margin | — | — | — | — | — | — | — | — | −1538.4% | — | — | — |
| Diluted EPS | $-0.13 | $-0.10 | $-0.08 | $-0.08 | $-0.14 | $-0.12 | $-0.11 | $-0.08 | $-0.10 | $-0.08 | $-0.11 | $-0.08 |
| EBITDA | -$27.0M | -$20.3M | -$18.0M | -$15.8M | -$21.0M | -$17.8M | -$16.4M | -$12.1M | -$14.9M | -$12.6M | -$15.2M | -$11.8M |
| Operating cash flow | -$14.7M | -$17.3M | -$13.3M | -$10.8M | -$11.8M | -$13.2M | -$9.2M | -$11.1M | -$10.8M | -$13.9M | -$12.4M | -$5.9M |
| Free cash flow | -$14.9M | -$17.4M | -$13.3M | -$10.9M | -$11.8M | -$13.2M | -$9.2M | -$11.1M | -$10.8M | -$13.9M | -$12.4M | -$5.9M |
| Diluted shares | 186.8M | 186.4M | 185.5M | 168.8M | 138.3M | 138.2M | 137.8M | 137.6M | 137.6M | 136.6M | 127.6M | 127.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $35.5M | $55.2M | $30.6M | $46.2M | $22.9M | $41.0M |
| Short-term investments | $144.4M | $139.5M | $178.3M | $173.7M | $78.1M | $71.6M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $190.2M | $205.2M | $219.6M | $231.3M | $116.7M | $131.5M |
| Total liabilities | $24.1M | $18.7M | $22.8M | $21.6M | $23.5M | $21.2M |
| Shareholders' equity | $166.0M | $186.5M | $196.8M | $209.6M | $93.2M | $110.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology